208 related articles for article (PubMed ID: 33049255)
21. Sarcomere mutation-specific expression patterns in human hypertrophic cardiomyopathy.
Helms AS; Davis FM; Coleman D; Bartolone SN; Glazier AA; Pagani F; Yob JM; Sadayappan S; Pedersen E; Lyons R; Westfall MV; Jones R; Russell MW; Day SM
Circ Cardiovasc Genet; 2014 Aug; 7(4):434-43. PubMed ID: 25031304
[TBL] [Abstract][Full Text] [Related]
22. Hypertrophic cardiomyopathy in myosin-binding protein C (
Adalsteinsdottir B; Burke M; Maron BJ; Danielsen R; Lopez B; Diez J; Jarolim P; Seidman J; Seidman CE; Ho CY; Gunnarsson GT
Open Heart; 2020; 7(1):e001220. PubMed ID: 32341788
[TBL] [Abstract][Full Text] [Related]
23. MYBPC3 in hypertrophic cardiomyopathy: from mutation identification to RNA-based correction.
Behrens-Gawlik V; Mearini G; Gedicke-Hornung C; Richard P; Carrier L
Pflugers Arch; 2014 Feb; 466(2):215-23. PubMed ID: 24337823
[TBL] [Abstract][Full Text] [Related]
24. Impact of systolic dysfunction in genotyped hypertrophic cardiomyopathy.
Fujino N; Konno T; Hayashi K; Hodatsu A; Fujita T; Tsuda T; Nagata Y; Kawashiri MA; Ino H; Yamagishi M
Clin Cardiol; 2013 Mar; 36(3):160-5. PubMed ID: 23197398
[TBL] [Abstract][Full Text] [Related]
25. Short communication: the cardiac myosin binding protein C Arg502Trp mutation: a common cause of hypertrophic cardiomyopathy.
Saltzman AJ; Mancini-DiNardo D; Li C; Chung WK; Ho CY; Hurst S; Wynn J; Care M; Hamilton RM; Seidman GW; Gorham J; McDonough B; Sparks E; Seidman JG; Seidman CE; Rehm HL
Circ Res; 2010 May; 106(9):1549-52. PubMed ID: 20378854
[TBL] [Abstract][Full Text] [Related]
26. Translational investigation of electrophysiology in hypertrophic cardiomyopathy.
Flenner F; Jungen C; Küpker N; Ibel A; Kruse M; Koivumäki JT; Rinas A; Zech ATL; Rhoden A; Wijnker PJM; Lemoine MD; Steenpass A; Girdauskas E; Eschenhagen T; Meyer C; van der Velden J; Patten-Hamel M; Christ T; Carrier L
J Mol Cell Cardiol; 2021 Aug; 157():77-89. PubMed ID: 33957110
[TBL] [Abstract][Full Text] [Related]
27. A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.
Seeger T; Shrestha R; Lam CK; Chen C; McKeithan WL; Lau E; Wnorowski A; McMullen G; Greenhaw M; Lee J; Oikonomopoulos A; Lee S; Yang H; Mercola M; Wheeler M; Ashley EA; Yang F; Karakikes I; Wu JC
Circulation; 2019 Feb; 139(6):799-811. PubMed ID: 30586709
[TBL] [Abstract][Full Text] [Related]
28. Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: evidence from patients and zebrafish models.
Hodatsu A; Konno T; Hayashi K; Funada A; Fujita T; Nagata Y; Fujino N; Kawashiri MA; Yamagishi M
Am J Physiol Heart Circ Physiol; 2014 Dec; 307(11):H1594-604. PubMed ID: 25281569
[TBL] [Abstract][Full Text] [Related]
29. Homozygous mutation of MYBPC3 associated with severe infantile hypertrophic cardiomyopathy at high frequency among the Amish.
Zahka K; Kalidas K; Simpson MA; Cross H; Keller BB; Galambos C; Gurtz K; Patton MA; Crosby AH
Heart; 2008 Oct; 94(10):1326-30. PubMed ID: 18467358
[TBL] [Abstract][Full Text] [Related]
30. Gene therapy strategies in the treatment of hypertrophic cardiomyopathy.
Prondzynski M; Mearini G; Carrier L
Pflugers Arch; 2019 May; 471(5):807-815. PubMed ID: 29971600
[TBL] [Abstract][Full Text] [Related]
31. Variable cardiac myosin binding protein-C expression in the myofilaments due to MYBPC3 mutations in hypertrophic cardiomyopathy.
Parbhudayal RY; Garra AR; Götte MJW; Michels M; Pei J; Harakalova M; Asselbergs FW; van Rossum AC; van der Velden J; Kuster DWD
J Mol Cell Cardiol; 2018 Oct; 123():59-63. PubMed ID: 30170119
[TBL] [Abstract][Full Text] [Related]
32. Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy.
Erdmann J; Raible J; Maki-Abadi J; Hummel M; Hammann J; Wollnik B; Frantz E; Fleck E; Hetzer R; Regitz-Zagrosek V
J Am Coll Cardiol; 2001 Aug; 38(2):322-30. PubMed ID: 11499719
[TBL] [Abstract][Full Text] [Related]
33. A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy.
Girolami F; Olivotto I; Passerini I; Zachara E; Nistri S; Re F; Fantini S; Baldini K; Torricelli F; Cecchi F
J Cardiovasc Med (Hagerstown); 2006 Aug; 7(8):601-7. PubMed ID: 16858239
[TBL] [Abstract][Full Text] [Related]
34. Prognostic predictive value of gene mutations in Japanese patients with hypertrophic cardiomyopathy.
Chida A; Inai K; Sato H; Shimada E; Nishizawa T; Shimada M; Furutani M; Furutani Y; Kawamura Y; Sugimoto M; Ishihara J; Fujiwara M; Soga T; Kawana M; Fuji S; Tateno S; Kuraishi K; Kogaki S; Nishimura M; Ayusawa M; Ichida F; Yamazawa H; Matsuoka R; Nonoyama S; Nakanishi T
Heart Vessels; 2017 Jun; 32(6):700-707. PubMed ID: 27885498
[TBL] [Abstract][Full Text] [Related]
35. An Update on MYBPC3 Gene Mutation in Hypertrophic Cardiomyopathy.
Tudurachi BS; Zăvoi A; Leonte A; Țăpoi L; Ureche C; Bîrgoan SG; Chiuariu T; Anghel L; Radu R; Sascău RA; Stătescu C
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445689
[TBL] [Abstract][Full Text] [Related]
36. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations.
Girolami F; Ho CY; Semsarian C; Baldi M; Will ML; Baldini K; Torricelli F; Yeates L; Cecchi F; Ackerman MJ; Olivotto I
J Am Coll Cardiol; 2010 Apr; 55(14):1444-53. PubMed ID: 20359594
[TBL] [Abstract][Full Text] [Related]
37. Allelic imbalance and haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathy.
Glazier AA; Thompson A; Day SM
Pflugers Arch; 2019 May; 471(5):781-793. PubMed ID: 30456444
[TBL] [Abstract][Full Text] [Related]
38. Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy.
Erdmann J; Daehmlow S; Wischke S; Senyuva M; Werner U; Raible J; Tanis N; Dyachenko S; Hummel M; Hetzer R; Regitz-Zagrosek V
Clin Genet; 2003 Oct; 64(4):339-49. PubMed ID: 12974739
[TBL] [Abstract][Full Text] [Related]
39. The Metabolome in Finnish Carriers of the MYBPC3-Q1061X Mutation for Hypertrophic Cardiomyopathy.
Jørgenrud B; Jalanko M; Heliö T; Jääskeläinen P; Laine M; Hilvo M; Nieminen MS; Laakso M; Hyötyläinen T; Orešič M; Kuusisto J
PLoS One; 2015; 10(8):e0134184. PubMed ID: 26267065
[TBL] [Abstract][Full Text] [Related]
40. Clinical Characteristics and Long-Term Outcome of Hypertrophic Cardiomyopathy in Individuals With a MYBPC3 (Myosin-Binding Protein C) Founder Mutation.
van Velzen HG; Schinkel AFL; Oldenburg RA; van Slegtenhorst MA; Frohn-Mulder IME; van der Velden J; Michels M
Circ Cardiovasc Genet; 2017 Aug; 10(4):. PubMed ID: 28794111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
